Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Roslye Berrios"'
Autor:
M Elvira Balcells, Nicole Le Corre, Josefina Durán, María Elena Ceballos, Cecilia Vizcaya, Sebastián Mondaca, Martín Dib, Ricardo Rabagliati, Mauricio Sarmiento, Paula I Burgos, Manuel Espinoza, Marcela Ferrés, Constanza Martinez-Valdebenito, Cinthya Ruiz-Tagle, Catalina Ortiz, Patricio Ross, Sigall Budnik, Sandra Solari, María de los Ángeles Vizcaya, Hanns Lembach, Roslye Berrios-Rojas, Felipe Melo-González, Mariana Ríos, Alexis M Kalergis, Susan M Bueno, Bruno Nervi
Publikováno v:
Clinical Infectious Diseases. 75:e594-e602
Background Inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have been widely implemented in low- and middle-income countries. However, immunogenicity in immunocompromised patients has not been established. Herein, we
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0eb96c05f1b0f627acab52ee9ece9259
https://doi.org/10.1093/cid/ciac167
https://doi.org/10.1093/cid/ciac167
Autor:
Roslye Berrios, Cristian Gutierrez-Vera, Bárbara M. Schultz, Patricio Andres Astudillo Paredes, GUILLERMO HOPPE ELSHOLZ, Luisa Fernanda Duarte Peñaloza, Andrea Schilling Redlich, Jorge Soto, Richard Garcia, Felipe Melo-Gonzalez, Fernando Valiente-Echeverria
BackgroundMultiple vaccines against SARS-CoV-2 have been evaluated in clinical trials, but very few include the pediatric population. The inactivated vaccine CoronaVac® has shown to be safe and immunogenic in a phase 1/2 clinical trial in a pediatri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::17d3c1de18a9519ff852cfacd1ca94e9
https://doi.org/10.1101/2022.02.15.22270973
https://doi.org/10.1101/2022.02.15.22270973
